| Literature DB >> 10218857 |
R Martino1, A Shah, P Romero, S Brunet, J Sierra, A Domingo-Albós, S Fruchtman, L Isola.
Abstract
Waldenstrom's disease is a lymphoproliferative disorder that is typically treated with plasmapheresis and/or alkylating agents. In young patients, other lymphoproliferative disorders have been treated with allogeneic transplantation. Two patients with aggressive Waldenstrom's disease, who progressed in spite of multi-agent chemotherapy and autologous stem cell transplantation, in one case, underwent allogeneic transplantation from their HLA-identical donors. Both remain alive with event-free survivals of more than 3, and more than 9 years, respectively. Allogeneic transplantation should be considered for young patients with Waldenstrom's disease.Entities:
Mesh:
Year: 1999 PMID: 10218857 DOI: 10.1038/sj.bmt.1701633
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483